FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167208319> ?p ?o ?g. }

• W3167208319 endingPage "n1537" @default.
• W3167208319 startingPage "n1537" @default.
• W3167208319 abstract "To assess the associations between statins and adverse events in primary prevention of cardiovascular disease and to examine how the associations vary by type and dosage of statins.Systematic review and meta-analysis.Studies were identified from previous systematic reviews and searched in Medline, Embase, and the Cochrane Central Register of Controlled Trials, up to August 2020.Randomised controlled trials in adults without a history of cardiovascular disease that compared statins with non-statin controls or compared different types or dosages of statins were included.Primary outcomes were common adverse events: self-reported muscle symptoms, clinically confirmed muscle disorders, liver dysfunction, renal insufficiency, diabetes, and eye conditions. Secondary outcomes included myocardial infarction, stroke, and death from cardiovascular disease as measures of efficacy.A pairwise meta-analysis was conducted to calculate odds ratios and 95% confidence intervals for each outcome between statins and non-statin controls, and the absolute risk difference in the number of events per 10 000 patients treated for a year was estimated. A network meta-analysis was performed to compare the adverse effects of different types of statins. An Emax model based meta-analysis was used to examine the dose-response relationships of the adverse effects of each statin.62 trials were included, with 120 456 participants followed up for an average of 3.9 years. Statins were associated with an increased risk of self-reported muscle symptoms (21 trials, odds ratio 1.06 (95% confidence interval 1.01 to 1.13); absolute risk difference 15 (95% confidence interval 1 to 29)), liver dysfunction (21 trials, odds ratio 1.33 (1.12 to 1.58); absolute risk difference 8 (3 to 14)), renal insufficiency (eight trials, odds ratio 1.14 (1.01 to 1.28); absolute risk difference 12 (1 to 24)), and eye conditions (six trials, odds ratio 1.23 (1.04 to 1.47); absolute risk difference 14 (2 to 29)) but were not associated with clinically confirmed muscle disorders or diabetes. The increased risks did not outweigh the reduction in the risk of major cardiovascular events. Atorvastatin, lovastatin, and rosuvastatin were individually associated with some adverse events, but few significant differences were found between types of statins. An Emax dose-response relationship was identified for the effect of atorvastatin on liver dysfunction, but the dose-response relationships for the other statins and adverse effects were inconclusive.For primary prevention of cardiovascular disease, the risk of adverse events attributable to statins was low and did not outweigh their efficacy in preventing cardiovascular disease, suggesting that the benefit-to-harm balance of statins is generally favourable. Evidence to support tailoring the type or dosage of statins to account for safety concerns before starting treatment was limited.PROSPERO CRD42020169955." @default.
• W3167208319 created "2021-06-22" @default.
• W3167208319 creator A5003352314 @default.
• W3167208319 creator A5023825635 @default.
• W3167208319 creator A5024848912 @default.
• W3167208319 creator A5024883388 @default.
• W3167208319 creator A5033368484 @default.
• W3167208319 creator A5058622593 @default.
• W3167208319 creator A5064190054 @default.
• W3167208319 creator A5081151451 @default.
• W3167208319 creator A5087460590 @default.
• W3167208319 creator A5087892176 @default.
• W3167208319 creator A5090429566 @default.
• W3167208319 date "2021-07-14" @default.
• W3167208319 modified "2023-10-14" @default.
• W3167208319 title "Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses" @default.
• W3167208319 cites W1140732306 @default.
• W3167208319 cites W1495967812 @default.
• W3167208319 cites W1500963439 @default.
• W3167208319 cites W1816597323 @default.
• W3167208319 cites W1824295310 @default.
• W3167208319 cites W1964694228 @default.
• W3167208319 cites W1967006339 @default.
• W3167208319 cites W1968240228 @default.
• W3167208319 cites W1974005985 @default.
• W3167208319 cites W1976358806 @default.
• W3167208319 cites W1977456203 @default.
• W3167208319 cites W1978980987 @default.
• W3167208319 cites W1980501393 @default.
• W3167208319 cites W1982914740 @default.
• W3167208319 cites W1983422922 @default.
• W3167208319 cites W1995777506 @default.
• W3167208319 cites W1999832762 @default.
• W3167208319 cites W2015121141 @default.
• W3167208319 cites W2015503831 @default.
• W3167208319 cites W2017946113 @default.
• W3167208319 cites W2018938059 @default.
• W3167208319 cites W2026241165 @default.
• W3167208319 cites W2031185570 @default.
• W3167208319 cites W2039418122 @default.
• W3167208319 cites W2040155238 @default.
• W3167208319 cites W2040982838 @default.
• W3167208319 cites W2043059773 @default.
• W3167208319 cites W2043353709 @default.
• W3167208319 cites W2045691212 @default.
• W3167208319 cites W2046495263 @default.
• W3167208319 cites W2049184091 @default.
• W3167208319 cites W2066061852 @default.
• W3167208319 cites W2067231723 @default.
• W3167208319 cites W2069557124 @default.
• W3167208319 cites W2070410095 @default.
• W3167208319 cites W2073530393 @default.
• W3167208319 cites W2078919468 @default.
• W3167208319 cites W2081470412 @default.
• W3167208319 cites W2081471135 @default.
• W3167208319 cites W2082426685 @default.
• W3167208319 cites W2083086461 @default.
• W3167208319 cites W2093313595 @default.
• W3167208319 cites W2096790749 @default.
• W3167208319 cites W2098034696 @default.
• W3167208319 cites W2098923148 @default.
• W3167208319 cites W2102006980 @default.
• W3167208319 cites W2104657845 @default.
• W3167208319 cites W2106229961 @default.
• W3167208319 cites W2106734896 @default.
• W3167208319 cites W2107295258 @default.
• W3167208319 cites W2110065044 @default.
• W3167208319 cites W2111714105 @default.
• W3167208319 cites W2111777372 @default.
• W3167208319 cites W2115169717 @default.
• W3167208319 cites W2125435699 @default.
• W3167208319 cites W2126563293 @default.
• W3167208319 cites W2126678006 @default.
• W3167208319 cites W2129750583 @default.
• W3167208319 cites W2129817697 @default.
• W3167208319 cites W2133043280 @default.
• W3167208319 cites W2134159541 @default.
• W3167208319 cites W2134957055 @default.
• W3167208319 cites W2137983259 @default.
• W3167208319 cites W2144625636 @default.
• W3167208319 cites W2146571866 @default.
• W3167208319 cites W2149953840 @default.
• W3167208319 cites W2154704322 @default.
• W3167208319 cites W2155598961 @default.
• W3167208319 cites W2155798268 @default.
• W3167208319 cites W2156560844 @default.
• W3167208319 cites W2156880046 @default.
• W3167208319 cites W2157724767 @default.
• W3167208319 cites W2160313369 @default.
• W3167208319 cites W2160760242 @default.
• W3167208319 cites W2164089346 @default.
• W3167208319 cites W2164538768 @default.
• W3167208319 cites W2164542079 @default.
• W3167208319 cites W2298875012 @default.
• W3167208319 cites W2313998826 @default.
• W3167208319 cites W2319050272 @default.
• W3167208319 cites W2323976047 @default.
• W3167208319 cites W2331474768 @default.

• next